The landscape of federal autism policy is undergoing a seismic and contentious transformation. During a high-stakes meeting held on Thursday, the Interagency Autism Coordinating Committee (IACC) officially adopted a new, far-reaching strategic plan that signals a departure from long-standing scientific consensus. Despite rigorous objections from advocacy groups and researchers regarding the inclusion of debunked theories, the committee voted 26-1 to approve a roadmap that pivots away from traditional genetic research toward speculative areas of study, including inflammation, metabolic stress, and environmental “triggers” such as vaccinations.
The approval of this 336-page document marks the culmination of months of friction under the leadership of Health Secretary Robert F. Kennedy Jr., who reshaped the committee earlier this year to align more closely with his own views on public health and vaccine safety. As the committee moves to implement these nonbinding recommendations, the medical and disability advocacy communities remain deeply divided over the future of federal autism research.
The Shift: From Genetics to Speculation
For decades, the prevailing scientific approach to understanding autism has centered on genetics, neurobiology, and developmental support. The new IACC strategic plan, however, radically reshapes these priorities. While the document acknowledges the importance of addressing co-occurring conditions like epilepsy and sleep disorders—a move largely welcomed by the autistic community—it simultaneously directs significant federal resources toward areas that lack robust scientific backing.
The plan explicitly calls for investigating the roles of diet, metabolic stress, and folate in the manifestation of autism. Perhaps most controversially, it prioritizes research into "regression"—the loss of previously acquired language or social skills—by framing it through the lens of potential immunological or infectious causes. This pivot has alarmed experts who point out that the scientific community has repeatedly debunked the link between vaccines and autism, yet the committee’s rhetoric during the Thursday hearing suggested a renewed openness to such hypotheses.
"We don’t want to close the door for any potential trigger, and that would include things like glutamate or aspirin, or a vaccination," said Laura Cellini, CEO of Elucidate ASD, a nonprofit organization that advocates for medicalized treatments for autism. "We are quite open to investigating anything and everything. This plan closes no door."
Chronology of a Contentious Process
The path to Thursday’s vote was paved with administrative friction and public outcry. The process was defined by a series of events that critics argue undermined the democratic functions of a federal advisory body:
- July 17: IACC Chair Sylvia Fogel unveiled the 336-page draft of the strategic plan, providing the public with only three days to review and submit formal comments.
- Late July: A coalition of prominent autism advocacy and research organizations expressed immediate backlash, pressuring Fogel to delay the meeting. The pressure resulted in a temporary postponement, though the process remained fraught with allegations that the committee was failing to comply with federal advisory regulations.
- August (Pre-Meeting): The committee’s internal communications became strained as members expressed frustration over a lack of transparency.
- Wednesday, August (Pre-Meeting): A formal statement signed by 13 major advocacy organizations urged the committee to postpone the vote, citing insufficient time to review the massive influx of late-stage revisions.
- Thursday, August: During the final hearing, members received over 1,000 pages of additional comments and revisions less than 24 hours before the meeting—a timeline experts described as "infeasible" for professional deliberation.
Supporting Data and the "New Normal"
The IACC’s meeting was characterized by an atmosphere that several longtime observers described as a "new normal." During the public comment portion of the meeting, multiple individuals claimed that vaccines had caused their children’s "regression" into autism. Unlike in previous years, these claims went unchallenged by the committee members, a development that Greg Robinson, director of public policy at the Autistic Self Advocacy Network (ASAN), identified as a dangerous departure from evidence-based policymaking.
"We are seeing right now the harms that come from misinformation around vaccines," Robinson said, citing the recent reports of two measles deaths in Pennsylvania. "We know how it has led to promoting harmful ideas about autistic people, about autism, and about supposed cures or remedies for autism for autistic folks that have been harmful or even deadly in the past."
Furthermore, the committee’s methodology for gauging public sentiment has come under fire. Chair Sylvia Fogel utilized artificial intelligence to categorize thousands of public comments, claiming that 50% were "aligned" with the plan and 40% were "mixed." Critics, including committee member Scott Robertson, expressed concern over the transparency of this AI analysis and the lack of clarity regarding how the software reached its conclusions.
Official Responses and Internal Dissent
The internal dissent within the IACC reached a boiling point during the Thursday session. Scott Robertson, a senior policy adviser at the Labor Department who is himself autistic, emerged as the primary voice of opposition. He highlighted the logistical impossibility of reviewing 1,000 pages of material overnight and warned that the committee’s call for nearly doubling federal autism funding—from $390 million to $747 million—clashes with existing appropriations outlined in the Autism CARES Act.
"I can’t remember ever, prior to the adoption of a strategic plan, 13 awesome and significant disability organizations coming out and saying, ‘Please don’t rush through this kind of thing,’" Robertson noted.
Despite these objections, Chair Fogel remained resolute. She framed the decision to rush the vote as a necessary action to address "two decades of public comments" that she argued had been ignored by previous administrations. "Some of those agencies who made that statement were well represented on this committee for two decades," Fogel retorted. "We considered public comments more than ever in the history of this committee… I, as chair, am moving to act."
Implications for the Future of Autism Policy
The implications of this vote extend far beyond the committee room. By prioritizing research into unproven "triggers" and shifting focus away from the life-course outcomes that the autistic community has long championed—such as employment, housing, and independent living—the plan risks alienating the very people it is designed to support.
Sam Crane, an autistic self-advocate and former IACC public member, noted that while the recognition of co-occurring conditions like motor issues is a positive step, the underlying philosophy of the plan is deeply concerning. "Genetics is important, but it probably was overfunded," Crane acknowledged, but added that the focus on leucovorin and other folate-based therapies—which lack scientific evidence for efficacy in treating autism—suggests a pivot toward medical models that many in the disability community have fought to move away from.
The federal government appears ready to embrace this new direction. Secretary Kennedy has already begun acting on the committee’s recommendations, including the launch of a new "National Autism Missing and Endangered Person Alert" initiative. As the IACC continues to meet, the divide between the federal body and the broader scientific and disability community seems likely to widen.
For many, the committee’s assertion that it is "opening doors" is interpreted as a reopening of debates that were settled long ago. With the strategic plan now adopted, the coming years will serve as a litmus test for whether these nonbinding recommendations lead to meaningful improvements in the lives of autistic people or, as many fear, a regression into outdated, stigmatizing, and scientifically unsound approaches to autism care.
